<h3>Objectives:</h3> Racial disparities in clinical trial enrollment are ethically dubious and, in some cases, threaten the applicability of results beyond the studied population. The objective of this study is to assess racial diversity, and reporting thereof, in gynecologic oncology clinical trials. <h3>Methods:</h3> Clinical trials in gynecologic oncology were identified by searching ClinicalTrials.gov for the following cancer types: ovarian, uterine, endometrial, cervical, vaginal, and vulvar. Data collection was performed in February 2020. Data on these trials were downloaded from the website and supplemented with manual codification. We excluded trials that were currently active, duplicative, and/or not enrolling patients with gynecologic malignancies. Race and ethnicity data were extracted from participant demographics included on ClinicalTrials.gov; trials that did not include this data were considered non-reporters. <h3>Results:</h3> A total of 1882 trials met inclusion criteria, of which 179 (10%) reported the race of trial participants. Racial reporting in domestic trials was slightly higher compared to international trials, at 12% domestically vs 7% internationally. Of the trials that reported race, the majority of participants were White for both international and domestic U.S. trials, though international trials enrolled a higher proportion of White and Asian patients than domestic trials and a far lower percentage of Black/African American patients (Figure 1). Globally, 14% of the trials that reported race enrolled zero non-White participants, and 34% enrolled fewer than 10% non-White participants. Fourteen percent of industry funded trials reported race, higher than the global average of 10%. Industry funded trials enrolled a higher percentage of White participants (68%) as compared to non-industry funded trials (58%) globally. Reporting of race has increased from 4% for trials started 2000-2004, to 12% for trials started between 2014-2018. Between 2000-2004, 79% of participants were White, as compared to 63% between 2014-2018. <h3>Conclusions:</h3> There is a paucity of data about ethnic and racial composition of participants in gynecologic oncology clinical trials. The majority of trials do not provide demographic data on publicly accessible platforms. Where the data are reported, clinical trials for patients with gynecologic malignancies enroll White patients at rates that exceed the epidemiologic burden of disease. International and industry funded trials enroll a higher percentage of White participants than domestic and non-industry funded trials, respectively. Reporting rates and diversity of enrollees appear to be improving modestly with time.